Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD01 + PD04 + AD05
- Development stage
- Preclinical
- Lead developer
- AC Immune
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
PD01 + PD04 + AD05 is a combination active immunotherapy (vaccine) developed by AFFiRiS for the treatment of Dementia with Lewy bodies (DLB). The combination utilizes AFFiRiS's proprietary AFFITOME technology to target two key proteins associated with neurodegeneration: alpha-synuclein and amyloid-beta. PD01 and PD04 are AFFITOPE candidates designed to induce an immune response against pathological forms of alpha-synuclein (the primary component of Lewy bodies), while AD05 targets amyloid-beta (the primary component of amyloid plaques). By addressing both pathologies simultaneously, the combination aims to provide a more comprehensive therapeutic approach for DLB, where both protein aggregates are typically present. The individual components are short peptides that mimic the epitopes of the target proteins, formulated with an adjuvant to stimulate the production of specific antibodies. As of the latest reports, this combination is in the preclinical stage of development.
- Other names
- PD01A + PD04A + AD05
02
Targets
Amyloid-beta aggregate (N-terminal epitope)α-syn (Alpha-synuclein (pathological aggregates))
Beyond the preview
Go deeper on PD01 + PD04 + AD05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD01 + PD04 + AD05.